In-silico design and production of a novel antigenic chimeric Shigella IpaB fused to C-terminal of Clostridium perfringens enterotoxin.
This study aims to design, express, and purify a novel chimeric protein, as a serotype-independent vaccine candidate against Shigella containing full-length Shigella invasion plasmid antigen B (IpaB) and a C-terminal fragment (residues 194-319) of Clostridium perfringens enterotoxin (C-CPE) as a mucosal adjuvant. Several online databases and bioinformatics software were utilized to design the chimeric protein and the relative recombinant gene. The recombinant gene encoding IpaB-CPE194-319 was synthesized, cloned into pACYCDuet-1 expression vector, and transferred to E. coli Bl21 (DE3) cells. IpaB-CPE194-319 was then expressed in auto-induction medium, purified and characterized using MALDI-TOF-TOF mass spectrometry. Followed by subcutaneous injection of the purified IpaB-CPE194-319 to BALB/c mice, antigenicity of this chimeric protein was determined through performing dot-blot immunoassay on nitrocellulose membrane using mice sera. The outcomes of this study show the successful design, efficient expression, and purification of IpaB-CPE194-319 divalent chimeric protein under mentioned conditions. The obtained results also demonstrate the intrinsic antigenic property of IpaB-CPE194-319. PMID: 31473892 [PubMed - as supplied by publisher]
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Zhenguang Liu, Lin Yu, Pengfei Gu, Ruonan Bo, Adelijiang Wusiman, Jiaguo Liu, Yuanlaing Hu, Deyun Wang
Authors: Ferella A, Aguirreburualde MSP, Sammarruco A, Parreño V, Santos MJD, Mozgovoj M Abstract Bovine respiratory syncytial virus (BRSV) is one of the most relevant agents responsible for respiratory disease in cattle from both dairy and beef farms. BRSV is spread by horizontal contact causing a constant presence of seropositive animals that favors viral circulation throughout the year. Moreover, reinfections with BRSV are frequent between animals regardless of their age as BRSV does not confer long-lasting protective immunity. Several studies have demonstrated the circulation of BRSV in cattle from diffe...
CONCLUSIONS: Immunization Information System is an essential technological innovation for the management of immunization actions. However, the production of timely records and the use of information are still challenges. Investments in training are required to ensure System's management and operationalization activities. PMID: 32490998 [PubMed - in process]
Are there seasonal variations in resistance to fluoroqinolones and other antimicrobial agents among community-acquired urinary E. coli infections?American Journal of Epidemiology
[Thomson Reuters Foundation] Rome -Thursday's GAVI vaccine summit aims to help people in the developing world get access to any eventual coronavirus vaccine. What are the obstacles?
The GAVI vaccines alliance said on Thursday it had raised $8.8 billion from international donor governments, companies and philanthropic foundations to fund its immunisation programmes through to 2025.
Novavax Inc said on Thursday the U.S. Department of Defense (DoD) will give the late-stage biotech company up to $60 million to fund the manufacturing of its experimental COVID-19 vaccine.
Publication date: Available online 4 June 2020Source: Journal of Global Antimicrobial ResistanceAuthor(s): Tsolaire Sourenian, David Mann, Shaoting Li, Xiangyu Deng, Hadi Jaafar, Issmat I. Kassem
Conclusion This study confirms the in vitro antibacterial activity of BIOCITRO® against Gram-negative and Gram-positive bacteria. For most of the strains, the product reached the bactericidal effect at the same concentration of the bacteriostatic effect and maximum difference between MIC and MBC was two dilution steps. The less susceptible species of the study were S. enterica ssp. enterica and E. coli with MBC90 values of 256 and 128 μg/mL, respectively, while the most susceptible was C. perfringens with MBC90 of 16 μg/mL. After short exposition time to the product, the significant effect over the viability of ...
People who live in cities are used to the company of furry vermin. But a new study reveals that mice and men may be sharing much more than just living quarters. In a study published in the journal mBio, researchers led by Dr. Ian Lipkin, professor of epidemiology at the Mailman School of Public Health at Columbia University, studied the gut microbes of 416 mice collected from mostly residential buildings all over New York City. Lipkin and his team did a thorough genetic analysis of the microbes they extracted from the feces of the mice, and found that they contained a number of disease-causing bacteria. Nearly 40% of the ...